Roivant Sciences (ROIV) Prepaid Assets (2021 - 2026)
Roivant Sciences' (ROIV) quarterly Prepaid Assets came in at $105.3 million in Q1 2026, down 6.94% YoY from $113.2 million in Q1 2025, and down 18.93% on a QoQ basis from $129.9 million in Q4 2025.
Roivant Sciences (ROIV) Prepaid Assets (2021 - 2026) Analysis & Trends
Roivant Sciences (ROIV) has 6 years of Prepaid Assets data on file, last reported at $105.3 million in Q1 2026.
- Quarterly Prepaid Assets fell 6.94% year-over-year to $105.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $105.3 million (down 6.94% YoY) and the FY2026 annual result came in at $105.3 million, down 6.94% from the prior year.
- Prepaid Assets eased to $105.3 million in Q1 2026, from $129.9 million in the prior quarter.
- In the past five years, Prepaid Assets ranged from a high of $323.0 million in Q2 2024 to a low of $53.4 million in Q1 2022.
- A 5-year average of $103.1 million and a median of $93.3 million in 2022 frame the typical range for Prepaid Assets.
- Annual changes were most pronounced in 2024 — Prepaid Assets soared 399.53% — and 2025, when it tumbled 65.14%.
- Tracing ROIV's Prepaid Assets over 5 years: stood at $69.5 million in 2022, then soared by 95.55% to $135.9 million in 2023, then plunged by 57.58% to $57.7 million in 2024, then jumped by 125.32% to $129.9 million in 2025, then decreased by 18.93% to $105.3 million in 2026.
- The last three Prepaid Assets figures came in at $105.3 million (Q1 2026), $129.9 million (Q4 2025), and $125.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 128.37 Mn |
| Mar 31, 2026 | 105.32 Mn |
| Dec 31, 2025 | 129.91 Mn |
| Sep 30, 2025 | 125.81 Mn |
| Jun 30, 2025 | 112.60 Mn |
| Mar 31, 2025 | 113.17 Mn |
| Dec 31, 2024 | 57.66 Mn |
| Sep 30, 2024 | 54.84 Mn |
| Jun 30, 2024 | 322.99 Mn |
| Mar 31, 2024 | 80.61 Mn |
| Dec 31, 2023 | 135.92 Mn |
| Sep 30, 2023 | 60.72 Mn |
| Jun 30, 2023 | 64.66 Mn |
| Mar 31, 2023 | 60.83 Mn |
| Dec 31, 2022 | 69.51 Mn |
| Sep 30, 2022 | 111.85 Mn |
| Jun 30, 2022 | 93.27 Mn |
| Mar 31, 2022 | 53.37 Mn |
| Dec 31, 2021 | 70.33 Mn |
| Sep 30, 2021 | 55.56 Mn |